abstract |
This therapeutic agent for Nakajo-Nishimura syndrome comprises a histone deacetylase inhibitor, wherein the histone deacetylase inhibitor may be: at least one compound selected from the group consisting of CUDC-907, JNJ-26481585, LAQ824, romidepsin, and trichostatin A; a pharmaceutically acceptable salt thereof; or solvates thereof. |